Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide–based haploidentical versus matched sibling donor reduced-intensity …
Biology of blood and marrow transplantation, 2019•Elsevier
Classic Hodgkin lymphoma (cHL) patients with relapsed or refractory disease may benefit
from allogeneic hematopoietic cell transplantation (allo-HCT), but many lack a matched
sibling donor (MSD). Herein, we compare outcomes of 2 reduced-intensity conditioning
(RIC) HCT platforms in cHL: T cell–replete related donor haploidentical (haplo) HCT with a
post-transplant cyclophosphamide (PTCy)-based approach versus an MSD/calcineurin
inhibitor (CNI)-based approach. The study included 596 adult patients who underwent a first …
from allogeneic hematopoietic cell transplantation (allo-HCT), but many lack a matched
sibling donor (MSD). Herein, we compare outcomes of 2 reduced-intensity conditioning
(RIC) HCT platforms in cHL: T cell–replete related donor haploidentical (haplo) HCT with a
post-transplant cyclophosphamide (PTCy)-based approach versus an MSD/calcineurin
inhibitor (CNI)-based approach. The study included 596 adult patients who underwent a first …
Abstract
Classic Hodgkin lymphoma (cHL) patients with relapsed or refractory disease may benefit from allogeneic hematopoietic cell transplantation (allo-HCT), but many lack a matched sibling donor (MSD). Herein, we compare outcomes of 2 reduced-intensity conditioning (RIC) HCT platforms in cHL: T cell–replete related donor haploidentical (haplo) HCT with a post-transplant cyclophosphamide (PTCy)-based approach versus an MSD/calcineurin inhibitor (CNI)-based approach. The study included 596 adult patients who underwent a first RIC allo-HCT for cHL between 2008 and 2016 using either a haplo-PTCy (n = 139) or MSD/CNI-based (n = 457) approach. Overall survival (OS) was the primary endpoint. Secondary endpoints included acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD), nonrelapse mortality (NRM), relapse/progression, and progression-free survival (PFS). On multivariate analysis, there was no significant difference between haplo/PTCy and MDS/CNI-based approaches in terms of OS (hazard ratio [HR], 1.07; 95% confidence interval [CI], .79 to 1.45; P = .66) or PFS (HR, .86; 95% CI, .68 to 1.10; P = .22). Haplo/PTCy was associated with a significantly higher risk of grades II to IV aGVHD (odds ratio [OR], 1.73, 95% CI, 1.16 to 2.59; P = .007), but the risk of grades III to IV aGVHD was not significantly different between the 2 cohorts (OR, .61; 95% CI, .29 to 1.27; P = .19). The haplo/PTCy platform provided a significant reduction in cGVHD risk (HR, .45; 95% CI, .32 to .64; P < .001), and a significant reduction in relapse risk (HR, .74; 95% CI, .56 to .97; P = .03). There was a statistically nonsignificant trend toward higher NRM with a haplo/PTCy approach (HR, 1.65; 95% CI, .99 to 2.77; P = .06). Haplo/PTCy-based approaches are associated with lower incidences of cGVHD and relapse, with PFS and OS outcomes comparable with MSD/CNI-based approaches. There was a leaning toward higher NRM with a haplo/PTCy-based platform. These data show that haplo/PTCy allo-HCT in cHL results in survival comparable with MSD/CNI-based allo-HCT.
Elsevier
